Figure 1. Incidence of GIB in the subgroups. GIB: gastrointestinal bleeding.
| Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc |
| Journal website https://www.gastrores.org |
Original Article
Volume 13, Number 4, August 2020, pages 146-149
Does Extended Use of Clopidogrel-Based Dual Anti-Platelet Therapy Increase the Risk of Gastrointestinal Bleeding?
Figure
Tables
| Demographic feature | Standard use of CDAPT (n = 75) | Extended use of CDAPT (n = 276) | P value |
|---|---|---|---|
| NSAID: non-steroidal anti-inflammatory drug; DOAC: direct oral anticoagulant; VKA: vitamin K antagonists. | |||
| Gender | |||
| Male | 37 (49%) | 140 (51%) | 0.79 |
| Female | 38 (51%) | 136 (49%) | 0.79 |
| Mean age | 63 | 65 | 0.16 |
| Use of NSAID/DOAC/VKA | 1 (1.5%) | 13 (5%) | 0.2 |
| GIB in extended use of dual-antiplatelet therapy | GIB in recommended use of dual-antiplatelet therapy | P value | |
|---|---|---|---|
| GIB: gastrointestinal bleeding. | |||
| Total population (%) | 22 | 16 | 0.26 |
| Male (%) | 25 | 8 | 0.04 |
| Female (%) | 20 | 24 | 0.65 |